To understand the significance of this development, one needs to understand how traditional allergy shots are made. Currently, allergy companies purify a protein called Fel d1 from cats and make a vial out of it. This purification process is like removing the corn kernels from a cornstalk to put into a can to sell at the supermarket.
Peptide immunotherapy as described in this new research is like making the "essence" of the corn kernel in the lab. For this cat vaccine, the key molecule created is a 7 amino acid long peptide sequence.
The benefits of this novel treatment is the lack of side-effects when the shots are administered (meaning, no waiting around after the shot)... and only four to eight shots per year are required (rather than the weekly injections with current allergy shots).
The optimal dose to use is currently being determined in phase three clinical trials.
Reference:
Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol. 2011 Jan;127(1):89-97, 97.e1-14.
